- Iveric Bio is developing Zimura - indicated for Geographic Atrophy - an eye disease that often leads to blindness.
- Zimura has met its primary endpoint in a pivotal Phase 3 trial, and data from a fully enrolled second Phase 3 will be available in H222.
- Zimura's chief rival Pegcetacoplan, developed by Apellis, recently missed one primary endpoint and met another in its 2 Phase 3 trials in GA.
- That has opened the door for Zimura to become the first drug ever approved for GA - a multi-billion dollar market.
- Iveric is aiming to create a franchise with Zimura, targeting all forms of advanced macular degeneration. Everything hangs on the outcome of its second pivotal trial.
For further details see:
Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field